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Abstract
Background: ProvLab Alberta provides all laboratory testing for Bordetella pertussis including sporadic cases and
outbreak investigations through collaborations with provincial public health partners. We describe B. pertussis
activity in Alberta from July 2004 to December 2012.
Methods: Laboratory testing for pertussis was analyzed using interpreted laboratory data that was generated by
DIAL, a secure web-based platform. Duplicate specimens from the same individual ≤90 days were excluded to
generate a case-based dataset. Immunization status of confirmed pertussis cases from the provincial immunization
repository was reviewed.
Results: Overall, 7.1% of suspected pertussis cases tested positive with a higher positivity rate in outbreak as
compared to sporadic setting. Annual variations in sporadic pertussis cases were observed across the province with
higher positivity rates in 2005, 2008, 2009 and 2012. A significantly higher positivity rate was observed in a northern
region of Alberta. While the positivity rate in sporadic setting was highest in adolescents aged 10 to <15 years old
(14.8%), population-based disease burden was highest in young children <5 years old. Of the 81.6% (n = 1,348)
pertussis cases with immunization records, 48.3% were up-to-date with immunization. The pertussis cases that were
up-to-date with their immunization were older (median age 12.9 years) as compared to those with incomplete
(median age 9.7 years) or no pertussis immunization (median age 3.8 years).
Conclusions: Cyclic pattern of annual pertussis activity with geographic variation was observed in Alberta with no
obvious case finding effect from outbreak investigations. The high positivity rates in adolescents suggested an
underestimation of disease burden in this age group.
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Background
Bordetella pertussis is a highly contagious bacterial
pathogen that only infects humans and causes respiratory
infections that has a relatively predictable clinical course
including a catarrhal, paroxysmal and convalescent phase
[1-4]. Clinical severity of pertussis is highly variable
depending on the age at diagnosis, immunization status
and type of vaccine. Morbidities and mortality of pertus-
sis infections are highest in infants <3 months of age and
hospitalization rates in infants <1 year remained high in
most countries despite vaccine programs [2,4]. Analysis
of data from the Italian Trial on Acellular Pertussis
Vaccines with three distinct study periods showed that
the proportion of children with spasmodic cough, apnea,
cyanosis, and vomiting as well as the duration of cough
was lower in vaccinated children compared to those
without vaccine and that pertussis was milder after 3
years of age. Using a scale to rank key clinical symptoms
of pertussis, Preziosi et al. showed an overall 48% vaccine
efficacy in reducing disease severity among children with
a higher efficacy with whole-cell (67%) as compared to
acellular (32%) vaccine [5]. Pertussis infections usually
result in milder and atypical illness in adolescents and
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adults and a high index of suspicion is required for mak-
ing the diagnosis [4,6]. Adults have been identified as an
important source of infection of pertussis for neonates
and young infants who are at highest risk for severe mor-
bidity and mortality.
Alberta is a province in western Canada, with a popu-
lation of 3.8 million people as of 2012 with an almost
equal number of males and females. Eighteen percent of
the population belong to the age group 0–14 years, 70%
in the ages of 15–64 years and 11% are over 65 years old
[6]. Whole cell vaccine for pertussis was first introduced
in Alberta in 1939 and was replaced by acellular pertus-
sis vaccine in 1997 because of a lower side effect profile
[7]. Routine pertussis immunization in Alberta includes
a combination vaccine that protects against diphtheria,
tetanus, acellular pertussis, polio, and Haemophilus
influenzae type b which is given at 2, 4, 6 and 18 months
and a booster dose of diphtheria, tetanus, acellular per-
tussis and inactivated polio at 4–6 years of age. Before
2004, a booster dose of only tetanus and diphtheria was
given in grade 9. As of September 2004, Adacel™, a com-
bined diphtheria, tetanus, and acellular pertussis vaccine
for adolescents replaced the booster dose of Td in the
grade 9 school immunization program to provide add-
itional protection against pertussis for children in this age
group. The infant formulation of the pertussis vaccine,
with tetanus and diphtheria +/− inactivated polio +/−
Haemophilus influenza b vaccine, contains higher concen-
trations of B. pertussis antigens and is used in children
from 2 months until 7 years of age. The adolescent/adult
formulation contains lower concentrations of pertussis
antigens and diphtheria toxoid and is given to persons ≥7
years [8].
Pertussis surveillance in Canada is maintained by two
national systems: Canadian Notifiable Disease Surveil-
lance System and The Immunization Monitoring Pro-
gram ACTive (IMPACT). There has been a decrease of
the incidence of pertussis in Canada since the introduc-
tion of pertussis vaccines in the 1940’s. A 4-year period-
icity for epidemic pertussis has been observed in the
post-vaccine era in Canada [9] and an increase of pertus-
sis activity was noted in Alberta in 2012. Pertussis is a
notifiable disease in Alberta and under the Public Health
Act all cases that meet the case definition are to be
reported to the office of the Chief Medical Officer of
Health. Alberta uses the Public Health Agency of
Canada case definition of pertussis which includes i)
laboratory confirmation of B. pertussis by positive poly-
merase chain reaction (PCR) or isolation of this patho-
gen from a clinical specimen or ii) a person who is
epidemiologically linked to a laboratory confirmed case
having one or more of the following symptoms: paroxys-
mal cough of any duration, cough ending in vomiting or
with apnea, cough with inspiratory “whoop” [10]. In this
study, we examined the laboratory testing for pertussis
and the epidemiology of all laboratory confirmed cases
of pertussis in Alberta from July 1, 2004 to December
31, 2012.
Methods
Laboratory testing for pertussis
The Provincial Laboratory for Public Health (ProvLab)
operates as a single laboratory with two sites, Edmonton
and Calgary, in the province of Alberta. ProvLab under-
takes diagnostic testing for all cases of B. pertussis in
Alberta and surrounding Northern Territories. ProvLab
also provides laboratory testing for all outbreak investi-
gations through collaborations with provincial public
health partners. Prior to June 2004, direct fluorescent
antibody test and/or culture for B. pertussis was used to
test slides and/or nasopharyngeal swabs submitted to
ProvLab for pertussis testing. Since June 2004, ProvLab
has used a real-time PCR assay for the detection of the
IS481 element within B. pertussis from respiratory speci-
mens [11]. Specimens are reported as positive for B.
pertussis if the amplification curve is of good quality and
the crossing point is ≤ 35 cycles. The melting curves of
specimens that have a good quality amplification curve
and a crossing point >35 cycles are reviewed by technical
supervisor and microbiologist. A specimen that cannot
be interpreted as either positive or negative is reported
as indeterminate. All specimens tested positive by PCR
are cultured for B. pertussis on Regan-Lowe plates and
colonies with morphology and gram stain compatible
with Bordetella species are tested using Accu-MAb™
Plus Bordetella pertussis/parapertussis DFA (Delta Bio-
tech Inc., British Columbia, Canada) for identification.
Specimens associated with a suspected B. pertussis out-
break are assigned a specific Exposure Investigation (EI)
number for each outbreak.
Web-based platform for laboratory surveillance
Data Integration for Alberta Laboratories (DIAL) is a
secure web-based platform that is being used in ProvLab
to extract, interpret, collate and analyze testing data
[12]. DIAL extracts raw specimen data from ProvLab’s
Laboratory Information System and with its built-in
automated interpretation engine, provides clinical inter-
pretive results for specific pathogens. In the case of B.
pertussis, DIAL automatically assigns a final classifica-
tion to each specimen as PCR-positive, negative or inde-
terminate for pertussis and indicates whether the B.
pertussis isolate was cultured and archived. ProvLab pro-
vides laboratory investigations for all outbreaks in Al-
berta and the information related to all the outbreaks is
also available on the DIAL platform, including the loca-
tion, setting and geographic information of these out-
breaks, which can be easily accessed and analyzed.
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Case-based data for pertussis
Line list data for all specimens received at ProvLab for B.
pertussis testing from July 1, 2004 to December 31, 2012
were extracted from DIAL with patient demographics
and submitter information. DIAL assigns geographic
designation for specimens in the order of availability of
patient’s city of residence, submitting physician location,
and submitting location (hospital or clinic) in the Labora-
tory Information System. Only specimens from Alberta
were included in this study. An early study by van der
Zee et al. showed that 8-25% of the specimens still tested
positive by PCR at >30 days of illness [13]. Specimens
collected ≤ 90 days from the same individual were
excluded to create a stringent criterion to eliminate
duplicate specimens and create a case-based dataset.
Immunization records of confirmed pertussis cases were
linked to the provincial immunization repository and the
Communicable Disease Reporting System to determine
the immunization status of the cases [14].
Sporadic versus outbreak cases
All cases with no associated Exposure Investigation (EI)
number related to outbreak investigations were classified
as sporadic cases. For cases that were associated with an
EI number, we used DIAL to extract the location and
setting of the outbreak and classified each EI as either
community-based outbreak (COB) or facility-based out-
break (FOB). COBs were defined as outbreaks in
geographically-defined communities with higher than
normal pertussis activity. FOBs were defined as out-
breaks in facilities including schools, daycares, long-term
care, assisted living facilities, hospitals, households, and
other congregated settings. The age of the cases tested
in school outbreaks was reviewed as some of the school
outbreaks were extended to community-based investiga-
tions. School (grade 1–12) outbreaks where >25% of the
cases tested were younger than 2 years or older than 20
years were reclassified as COBs.
Data analysis
Excluding specimens tested as indeterminate for pertus-
sis, the positivity rate of pertussis in sporadic settings,
COBs and FOBs were compared using the chi-squared
test. Differences in positivity rate by annual distribution,
gender, and age groups in each setting were analyzed
using binary logistic regressions with Bonferroni correc-
tion for multiple comparisons performed for each variable
because of the three settings. Difference in geographic
distribution of positivity rate was performed only for
sporadic cases because of cases coming from multiple
regions for outbreaks designated in a single region as
related to travel. For annual comparison, data from January
to June 2004 was excluded as there were only 6 months of
data for 2004. Cases with unknown gender or age were
excluded from the respective comparison. The age of the
confirmed pertussis cases in sporadic and the two out-
break settings was compared using the Kruskal-Wallis
test. All statistical analyses were performed using IBM
SPSS Statistics Version 20.0.0. Crude population rate by
age group from 2005 to 2012 for all laboratory confirmed
pertussis cases was calculated using population data from
Statistics Canada [6].
Results
A total of 26,487 specimens were received at ProvLab
from July 1, 2004 to December 31, 2012 for B. pertussis
testing and 1,404 specimens were from out of province
and excluded from this study. Of the 25,083 specimens
from Alberta, 1,377 (5.5%) were also excluded because
pertussis testing was not performed due to reasons that
include inappropriate specimen types or transport
media, incomplete patient or submitter information, and
leakage during specimen transport. Of the remaining
specimens from Alberta, 454 patients had one or more
specimen submitted ≤90 days resulting in 500 (2.1%)
specimens being excluded as duplicates: 416 individuals
had one duplicate specimen, 33 had two, four had three
and one individual had six duplicate specimens. The
median time between duplicate specimens was 21 days
(interquartile range: 3–48 days). A total of 23,206 sus-
pected pertussis cases were included in the study with
21,784 (93.9%) cases from patients with only one speci-
men and 1,422 (6.1%) cases from 681 patients with >1
specimen per patient. The median time period between
specimens included from an individual was 432 days
(interquartile range: 216–920 days).
During the study period, one or more specimens were
submitted for pertussis testing for 45 outbreak investiga-
tions: 16 investigations were initiated in geographically
defined communities, nine in schools, and the remaining
outbreaks in a variety of settings including long-term
care or assisted living facilities (n = 9), households or
community gatherings (n = 6), hospitals (n = 2), daycare
(n = 1), and other settings (n = 2). Five of the nine school
outbreaks were extended to community-based investiga-
tions with a total of 283 of 887 (31.9%) suspected cases
in these outbreaks (range: 26.8-33.9%) being younger
than 2 years or older than 20 years and were reclassified
as COBs.
After removing duplicate specimens, a total of 21,484
suspected sporadic pertussis cases, 1,598 suspected cases
from 21 COBs, and 124 suspected cases from 24 FOBs
were investigated for pertussis. Overall, 7.1% (1,652/23,206)
cases tested positive for B. pertussis and 8 sporadic cases
tested as indeterminate. There was significant difference
in the positivity rate among the different settings, with
6.6% for sporadic cases, 12.0% for COBs and 30.6% for
FOBs respectively (p < 0.001, chi-squared test) (Table 1).
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The monthly distribution of overall test positivity rate for
pertussis is presented in Figure 1 and the pertussis cases
by the type of setting in Figure 2. The months of July,
August and September were most commonly identified
as the months with the top three positive rates for
pertussis from 2005 to 2012. The annual distribution of
suspected and confirmed sporadic pertussis cases and
cases associated with COBs and FOBs is summarized in
Table 1. There was no COB in 2010 and no FOB in 2011.
July to December 2004 had the highest number of out-
breaks with six COBs and five FOBs and this time period
also had the highest positivity rate for pertussis (Table 1).
Excluding the six months of data from 2004 and using
2005 as the reference year, significantly lower positive
rates were observed for sporadic pertussis in 2006 (5.1%),
2007 (4.8%), 2010 (3.0%) and 2011 (4.1%) as compared to
2005 (7.3%) (p < 0.01, binary logistic regression with Bon-
ferroni correction). The year 2008 had significantly differ-
ent positivity rates when compared to 2005 for COBs
and FOBs (p < 0.05 and p < 0.01, respectively, binary lo-
gistic regression with Bonferroni correction); the rate was
high for COBs in 2008 (50%) and low for FOBs in 2008
(9.4%).
Gender and age distribution for all three settings is
shown in Table 2. There was no significant difference in
terms of gender distribution for the different settings. Ex-
cluding cases with unknown age and using the ≤8 weeks
age group as the reference group, significantly higher
positive rates were identified in the 10 to <15 years
(14.8%) and 15 to <20 years (9.4%) age categories in the
sporadic setting. No significant difference was found in
the positivity rate among age groups in COBs and FOBs.
There was no significant difference in the median age of
confirmed pertussis cases in the sporadic setting, COBs
and FOBs: 12.0 years (range: 0.05 – 83 years), 11.3 years
(range: 0.2 – 51 years), and 11.4 years (range: 0.5 – 38
years), respectively (p > 0.05, Kruskal-Wallis test). The
overall positivity rate and crude population rate of all
laboratory-confirmed pertussis cases from 2005 to 2012
by age groups is summarized in Table 3. While the posi-
tivity rate is highest in the 10 to <15 year age group at
14.8% (Table 1), the crude population rate of laboratory-
confirmed pertussis cases is highest in children younger
than 5 years (27.5%) (Table 3).
Immunization records were obtained for 1,348 (81.6%)
pertussis cases, out of which 651 (48.3%) were up-to-
date for their pertussis immunization, 231 (17.1%) had
incomplete series and 466 (34.6%) were not immunized.
Excluding the 55 cases who were ≤8 weeks old, thus not
yet eligible for pertussis vaccine, there was significant
difference in the median age of different groups based
on their immunization status at the time of pertussis in-
fection. The median age for those who were up-to-date
for immunization was 12.9 years (interquartile range:
8.6-15.3), those with incomplete series were 9.7 years
(interquartile range: 3.1-15.3) and those who were not
vaccinated were 3.8 years (interquartile range: 0.9-9.0),
respectively (P < 0.001, Kruskal-Wallis test).
Alberta was designated into 9 health regions by geo-
graphic location in April 2003 and was reorganized into
five zones in 2009. For sporadic cases, the positivity rate
was significantly higher in Region 9 (12.8%), p < 0.001, bin-
ary logistic regression (Table 4). Only the health regions of
the cities or the facilities where the COBs and FOBs were
initiated are summarized in Table 4. Out of the 21 COBs,
10 had cases that were based in neighbouring regions.
Table 1 Annual distribution of B. pertussis in sporadic, community-based and facility-based outbreak settings
Sporadic cases Community-based outbreak Facility-based outbreak
Suspected Confirmed (%) No. of outbreaks Suspected Confirmed (%) No. of outbreaks Suspected Confirmed (%)
Complete period 21,484 1,423 (6.6)1 21 1,598 191 (12.0)1 24 124 38 (30.6)1
2004* 2,611 280 (10.7) 6 678 76 (11.2) 5 14 1 (7.1)
20052,3,4 4,175 304 (7.3) 3 79 12 (15.2) 4 42 20 (47.6)
2006 2,841 145 (5.1)2 2 220 17 (7.7) 1 1 0 (0.0)
2007 2,023 97 (4.8)2 1 6 6 (100.0) 2 11 0 (0.0)
2008 2,359 187 (7.9) 1 14 7 (50.0)3 5 32 3 (9.4)4
2009 1,905 116 (6.1) 3 319 44 (13.8) 3 4 0 (0.0)
2010 1,161 35 (3.0)2 0 0 NA 3 19 14 (73.7)
2011 1,157 47 (4.1)2 4 158 22 (13.9) 0 0 NA
2012 3,252 212 (6.5) 1 124 7 (5.6) 1 1 0 (0.0)
*Only 6 months of data included for 2004 (July to December).
1p < 0.001, Chi-squared test excluding eight sporadic cases with indeterminate PCR results.
2p < 0.01, binary logistic regression with Bonferroni correction using 2005 as the reference year excluding 2004 (6 months only).
3p < 0.05, binary logistic regression with Bonferroni correction using 2005 as the reference year excluding 2004 (6 months only) and 2010 (no community-based
outbreak).
4p < 0.05, binary logistic regression with Bonferroni correction using 2005 as the reference year excluding 2004 (6 months only) and 2011 (no facility-based
outbreak).
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Cases involved in FOBs also resided in different health re-
gions from the original outbreak site. Geographic compari-
son was not performed for COBs and FOBs, however
COBs in region 9 had a noticeably high positive rate of
72.2%.
Discussion
Using laboratory testing data we analyzed over eight
years of B. pertussis activity in the province of Alberta.
The DIAL platform was used to extract B. pertussis test-
ing data and outbreak information to categorize cases
into sporadic or outbreak settings. Reviewing the demo-
graphics of cases investigated in individual outbreaks
allowed the identification of school outbreaks which had
broader impact in the community and analysis of labora-
tory confirmed pertussis cases in three different settings.
The overall disease burden is underestimated as epidemi-
ologically linked cases were not included in the analysis.
Recently, a mixed B. holmesii and B. pertussis out-
break with 30% of holmesii cases was reported in Ohio,
United States [15] and some studies identified 3 to 9% of
B. holmesii in patients of all ages with B. holmesii or B.
pertussis using culture or PCR [16-19]. Results from
these studies questioned the validity of using PCR assay
targeting the IS481 element for B. pertussis surveillance
because of the cross-reactivity of the assay for both
species. In Alberta, the validation study of the IS481
PCR assay did not identify any B. holmesii from 808
specimens between 2003 and 2004 [20]. In the current
study, Bordetella species were cultured from ~ 50% of
PCR positive specimens and only two specimens tested
negative for B. pertussis by DFA and both were identified
as B. pertussis by 16S sequencing (data not shown).
While there is still a possibility of B. holmesii in PCR
positive and culture negative specimens, the proportion
of B. holmesii in Alberta is likely low, which has also been
reported in Ontario, Canada (< 2%) and in Finland and
Holland (0%) [21]. Readers should be aware that although
this cross reactivity has been discussed in many jurisdic-
tions, including Canada, there is no consensus on what
molecular targets should be used to identify pertussis.
This is due to multiple factors and the authors are
working with partners such as the National Molecular
Diagnostics User Group in Canada to address these gaps.
In Canada, over 4000 cases of pertussis per year have
been reported between 1900 and 2006 [22]. In Alberta,
pertussis activity peaked between the months of July and
September from 2005 to 2011. An autumn seasonality
for pertussis was also reported in other parts of Canada.
Between 1990 and 2000 in British Columbia, pertussis
Figure 1 Monthly distribution of confirmed B. pertussis cases and test positivity rate in Alberta (July 2004 – December 2012).
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Table 2 Gender and age distribution of B. pertussis in sporadic, community-based and facility-based outbreak settings
Sporadic cases Community-based outbreaks Facility-based outbreaks
Gender ratio Suspected Confirmed Suspected Confirmed Suspected Confirmed
Male: Female* 1:1.1 1:1.2 1:1.3 1:1.0 1:1.4 1:1.1
Age category Suspected Confirmed (%) Suspected Confirmed (%) Suspected Confirmed (%)
≤8 weeks1 1,024 55 (5.4) 8 0 (0.0) 0 NA
>8 weeks - <6 months 1,522 107 (7.0) 43 6 (14.0) 3 0 (0.0)
6 months - <18 months 2,414 108 (4.5) 105 15 (14.3) 7 2 (28.6)
18 months – <5 years 3,533 177 (5.0) 246 22 (8.9) 26 10 (38.5)
5 - <10 years 2,739 169 (6.2) 273 41 (15.0) 13 4 (30.8)
10 - <15 years 2,158 319 (14.8)1 311 61 (19.6) 22 15 (68.2)
15 - <20 years 1,339 126 (9.4)1 224 29 (12.9) 12 2 (16.7)
20 - <40 years 3,412 197 (5.8) 205 8 (3.9) 30 5 (16.7)
40 - <60 years 2,506 137 (5.5) 142 9 (6.3) 3 0 (0.0)
60 years and older 773 26 (3.4) 38 0 (0.0) 8 0 (0.0)
Unknown 64 2 (3.1) 3 0 (0.0) 0 NA
*443 (1.9%) of cases had unknown gender with 422 in sporadic setting and 21 in community-based outbreaks. Seven of the 443 (1.6%) cases tested positive for
pertussis with all confirmed cases in the sporadic setting.





























































































Figure 2 Monthly distribution of confirmed B. pertussis cases by the type of setting: sporadic, community-based and facility-based
outbreaks in Alberta (July 2004 – December 2012).
Fathima et al. BMC Infectious Diseases 2014, 14:48 Page 6 of 9
http://www.biomedcentral.com/1471-2334/14/48
were most often found in the months of July and peaked
between August and November [23]. A study in Toronto,
Ontario, identified most cases of pertussis between
August and November [24]. From the international per-
spective, a large study looking at 16 different European
countries examined the epidemiology of pertussis be-
tween 1998 and 2002 showed that 28% of pertussis cases
occurred from July to September [25].
In the current study, most pertussis cases (86%) in
Alberta were identified in the sporadic setting. In 2004,
several regions in Alberta experienced outbreaks and the
rate of pertussis in the province was 18.8/100,000 cases
with a total of 684 reported cases [26]. For the
six community-based outbreaks captured from July to
December 2004 in this study, three were school out-
breaks that had extended to the community and one of
those outbreaks contributed to 20% of the 357 outbreak-
related cases in the 6-month period (data not shown).
Most of the pertussis cases identified through COBs or
FOBs in the province were in the winter months, November
to March. Thirty-one (68.9%) of the 45 outbreaks with
pertussis testing were initiated between November to
March, which coincided with the higher incidence of
overall respiratory illness and outbreak investigations in
the winter.
The overall positivity rate in Alberta using the same
PCR assay from June 2004 to December 2005 was 7.1%,
which is similar to the 9.4% reported in the Greater
Toronto Area from 1993 to 2007 when two PCR assays
were utilized overtime [24]. Excluding data from 2004,
which represented only six months of data, higher case
loads and positivity rates were observed in 2005, 2008,
2009 and 2012 in Alberta. Our results were similar to
previous reports with annual peaks and an epidemic cycle
of every 2–5 years [9]. It is possible that there were biases
for case-finding by increased testing in 2005 and 2012 as
there were higher numbers of suspected sporadic cases in
those years. On the other hand, no obvious relationship
between higher sporadic activity and the number of
community-based outbreaks was observed in those years.
The reasons behind the changes in pertussis burden over
time in Alberta are not known. An ecological cross-
sectional study in Australia using archived seropreva-
lence data showed a higher proportion of low level
pertussis antibodies in the sampled population the year
before several years of high level pertussis activity
suggesting the effect of cyclic waning immunity [27]. A
potential research focus can look at emerging genetic
polymorphisms in B. pertussis clones in Alberta to deter-
mine geographical epidemiological trending. Shuel et al.
looks at B. pertussis in Ontario from 1998 to 2006 and
has found one predominant clone linked to epidemics in
Europe and Australia [28].
Table 3 Overall positivity rate and crude population rate
per 100,000 of confirmed B. pertussis by age groups in
Alberta








0 - <5 years (n = 441)* 5.4% 27.5
0- <1 years (n = 209)* 5.6% 62.3
5 years - <10 years (n = 182) 7.1% 10.6
10 years - <15 years (n = 273) 14.1% 15.4
15 years - <20 years (n = 95) 8.2% 4.9
20 years - <40 years (n = 167) 5.4% 1.9
40 years - <60 years (n = 113) 4.9% 1.4
60 years & up (n = 23) 3.2% 0.5
*The 0 - <1 year group is a subset of the 0 - <5 year group.
Table 4 Regional distribution of B. pertussis in Alberta in sporadic, community-based and facility-based outbreak
settings













Region 11 1,480 96 (6.5) 1 389 44 (11.3) 3 3 0 (0.0)
Region 2 830 37 (4.5) 1 11 0 (0.0) 1 0 NA
Region 3 2,994 171 (5.7) 0 8 1 (12.5) 1 14 12 (85.7)
Region 4 3,027 209 (6.9) 5 849 93 (11.0) 3 19 1 (5.3)
Region 5 863 44 (5.1) 4 90 12 (13.3) 4 22 7 (31.8)
Region 6 6,820 418 (6.1) 1 17 2 (11.8) 5 21 4 (19.0)
Region 7 1,965 129 (6.6) 3 35 2 (5.7) 5 15 6 (40.0)
Region 8 2,172 148 (6.8) 4 181 24 (13.3) 2 17 4 (23.5)
Region 9 1,333 171 (12.8)1 2 18 13 (72.2) 0 13 4 (30.8)
*Geographic comparison was not performed for community-based and facility-based outbreaks because outbreaks initiated in a specific region usually involved
residents from multiple regions because of travel.
1p < 0.001, binary logistic regression using region 1 as the reference group.
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Our study did not find a significant difference in gender,
which is consistent with previous data from Alberta [26]
and Ontario where roughly 50% of specimens submitted
were from females [24]. The annual positivity rate for
sporadic pertussis was highest for the 10 to <15 years age
group (14.8%). This is consistent with earlier Canadian
data where rates of 10 to <15 year olds from 2002–2004
were elevated compared to other children [26], and this
may be attributed to the lower efficacy of the combined
adsorbed diphtheria-tetanus-pertussis whole-cell vaccine
used in children in Canada between 1980 and 1997 [29].
Recent resurgence of pertussis with a shift towards higher
rate in adolescents and young adults has also been re-
ported in United States and Australia [30,31]. About half
of the pertussis cases in our study had completed their
immunization series with a median age of 12.9 years. Two
studies have shown a progressive increase in the odds for
pertussis infection with time passed since the last acellu-
lar pertussis dose in children with five doses of vaccines
supporting the role of waning immunity in this popula-
tion [28,32]. Because of the change in diagnostic assay
from culture to PCR in July 2004, pertussis burden before
and after the adolescent booster dose that was imple-
mented in September 2004 cannot be compared.
While the B. pertussis positivity rate was highest in young
adolescents, children younger than 5 years remained as the
group with highest disease burden at the population level
in Alberta. The lower test positivity rate in infants and young
children in sporadic setting could be due to over sampling,
which suggested that the disease burden in adolescent and
young adults were underestimated in Alberta with their
high test positivity rate. One extensive case-based study
found that household contacts were the cause of 48-55% of
B. pertussis transmission to the <1 year age group, which
support the importance of disease control and prevention
in adolescents and adults [33]. The severity of pertussis in
young infants was shown in a study in 25 pediatric inten-
sive care units in United Stated where 83% of the 124 crit-
ical cases were younger than 3 months old and had a 10%
mortality rate [34]. In September 2012, United Kingdom
started a pertussis vaccination program for pregnant
women in their third trimester in September 2012 as a
response to the increase in pertussis in young infants in 2012
[35]. In the United States, a recent study followed a 2009
birth cohort (4,131,019 infants) and found that trimester
dTAP vaccination of pregnant mothers significantly re-
duced infant pertussis cases, hospitalizations, and deaths
over postpartum cocooning strategies [36]. Clinical trials
are still ongoing in Canada to study the efficacy and safety
of this approach.
Over the study period, Region 9 had the highest positiv-
ity rate in sporadic cases and COBs. Region 9 is the
northernmost health region in Alberta, and is mostly
rural with multiple small towns and communities. Our
finding is consistent with Alberta’s neighbouring province,
Saskatchewan, where a 9-year study showed higher inci-
dence of pertussis disease as well as lower vaccination
rates in rural areas as compared to urban areas [37].
While lower vaccination rates have also been observed in
rural compared to urban areas in the province (data not
shown), other factors such as age distribution, population
density, and physicians testing behaviour in the different
regions might have contributed to the significantly higher
positivity rate in Region 9 as compared to other regions
that are also comprised of rural areas.
Conclusion
To our knowledge, this is the first paper in Canada that
looks at sporadic versus outbreak pertussis cases and
trending across different settings. Innovative platforms
such as DIAL support access to specimen-based data and
outbreak information required for the study. A cyclical
pattern of annual pertussis activity with geographic vari-
ation was observed in Alberta. Patients associated with
outbreaks would more likely be tested positive. We did
not find an obvious relationship of increased case finding
in sporadic setting due to outbreak investigations. The
high test positivity in the adolescents and young adults
compared to other age groups suggested that disease
burden in those populations was underestimated.
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